0000950170-24-101257.txt : 20240828 0000950170-24-101257.hdr.sgml : 20240828 20240828111117 ACCESSION NUMBER: 0000950170-24-101257 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240823 FILED AS OF DATE: 20240828 DATE AS OF CHANGE: 20240828 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yale Catriona CENTRAL INDEX KEY: 0001779308 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 241252602 MAIL ADDRESS: STREET 1: C/O AKERO THERAPEUTICS INC. STREET 2: 170 HARBOR WAY 3RD FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 ownership.xml 4 X0508 4 2024-08-23 0001744659 Akero Therapeutics, Inc. AKRO 0001779308 Yale Catriona 601 GATEWAY BOULEVARD SUITE 350 SOUTH SAN FRANCISCO CA 94080 false true false false Chief Development Officer true Common Stock 2024-08-23 4 M false 8851 0.615 A 84782 D Common Stock 2024-08-23 4 S false 8851 27.527 D 75931 D Common Stock 2024-08-26 4 M false 5200 0.615 A 81131 D Common Stock 2024-08-26 4 S false 5200 27.514 D 75931 D Stock Option (Right to Buy) 0.615 2024-08-23 4 M false 8851 0.00 D 2028-09-26 Common Stock 8851 24864 D Stock Option (Right to Buy) 0.615 2024-08-26 4 M false 5200 0.00 D 2028-09-26 Common Stock 5200 19664 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 28, 2024, previously adopted by the Reporting Person. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $27.69, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $27.59, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 3. The options are vested and currently exercisable. /s/ Jonathan Young, Attorney-in-Fact 2024-08-28